Rationale: Inhaled corticosteroids have been shown to decrease exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Their effects in patients with milder airflow obstruction remain unclear.
Chronic obstructive pulmonary disease (COPD) is a chronic syndrome that is associated with acute worsening of symptoms (1) . These events, known as exacerbations of COPD (eCOPD), have been associated with impaired health status, as well as increased morbidity and mortality (2) . Numerous pharmacotherapeutic options, including long-acting bronchodilators, inhaled corticosteroids (ICS), chronic antimicrobial agents, and roflumilast have been shown to decrease eCOPD frequency in select patient populations (1) (2) (3) . In an effort to move toward more personalized therapy (4), several investigative groups have examined the factors associated with an increased patient risk of experiencing an eCOPD; the most frequently cited is a history of events, with two events in the previous year considered the most stable and predictive (5) . The Global Initiative for Chronic Obstructive Lung Diseases therapeutic strategy recommends intensification of inhaled therapies, particularly the addition of ICS for patients at risk of an exacerbation, particularly in those with severe airflow obstruction, with a history of two or more eCOPD events or one or more events that require hospitalization (1) .
In SUMMIT (Study to Understand Mortality and Morbidity), we showed that inhaled treatment with the corticosteroid, fluticasone furoate (FF), and the long-acting b-agonist (LABA), vilanterol (VI), did not improve survival compared with placebo in patients with moderate COPD and heightened cardiovascular risk (6) . The present study describes the effects of FF, VI, and their combination (FF/VI) on eCOPD, an additional predefined endpoint, in a population with COPD who had milder COPD and without a prespecified requirement of previous eCOPD in whom we anticipated that this therapy might be beneficial.
Methods
Details of the study design and the analysis approach were published previously (7) .
Patients
All patients provided written informed consent. The study was approved by local ethics committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study is registered on clinicaltrials.gov as NCT01313676 (GSK Study number 113782).
Study Design
This was a prospective, double-blind, parallel group, placebo-controlled, event-driven randomized trial conducted at 1,368 centers in 43 countries. Eligible patients were 40 to 80 years old, diagnosed with COPD, and had a post-bronchodilator FEV 1 of >50 and <70% of the predicted value (8), a ratio of post-bronchodilator FEV 1 to FVC <0.70, and a score of >2 on the modified Medical Research Council dyspnea scale. Patients had to have a history, or be at increased risk, of cardiovascular disease (6) . Exclusion criteria included respiratory disorders other than COPD, lung reduction surgery, receiving long-term oxygen or oral corticosteroid therapy, severe heart failure (New York Heart Association functional class IV or ejection fraction ,30%) and life expectancy of ,3 years (7). Participants were allocated equally to one of four treatments: placebo; FF (100 mg; GlaxoSmithKline, Research Triangle Park, NC) VI (25 mg; GlaxoSmithKline) or the combination of FF and VI (100/25 mg, Relvar/Breo; GlaxoSmithKline) administered once daily as a dry powder with the use of an inhaler (Ellipta; GlaxoSmithKline). Exacerbations were assessed every 3 months and at the end of study treatment.
Outcome Measurements eCOPD were a predefined outcome. eCOPD were defined by use of treatment for increased respiratory symptoms according to the judgment of the investigator. Moderate exacerbations were defined as a symptomatic deterioration treated with antibiotic agents (AB) and/or systemic corticosteroids (SCS), whereas severe eCOPD were those that led to hospital admission. We had information on treatment with AB and SCS separately for moderate exacerbations, which allowed analyses by exacerbation treatment.
Statistical Analysis
The analyses of time to first exacerbation and rate of exacerbations to compare between treatment arms in the intention-totreat population (moderate and/or severe, hospitalized, and treated with SCS with or without AB) were prespecified, whereas analyses of subgroups and analyses of exacerbations treated with other combinations (i.e., treated with SCS alone, AB alone, and or both SCS and AB) were post hoc. Event-based numbers needed to treat (NNTs) were calculated (9) . All P values should be interpreted as nominal because the primary outcome did not meet statistical significance (6) .
To control for multiplicity, a closed testing procedure approach was planned. If significance at the 5% level was not achieved for the primary endpoint for the comparison of combination treatment with placebo, then the tests for the secondary and other efficacy endpoints would be interpreted as descriptive only. Time to first exacerbation was analyzed using a Cox proportional hazards regression model that allowed for covariates of age, sex, and previous exacerbations (0, 1, and >2). The frequency of eCOPD was analyzed using a negative binomial model with the number of exacerbations as the outcome and the logarithm of time during which treatment was received as an offset variable.
These same analyses were performed within each individual subgroup (smoking status, age, cardiovascular entry criteria, sex, ethnicity, race, region, percent of predicted FEV 1 , history of moderate and/or severe exacerbations and history of hospitalized exacerbations). Because of the impact of seasons on exacerbation rates (10, 11) and therapy (12), we separated exacerbations into those that occurred in winter or summer. trial was provided by a scientific steering committee composed of six academic researchers and three employees from GlaxoSmithKline who were collectively responsible for the study design and conduct, for approval of the statistical analysis plan, and for the review and interpretation of the data. Statistical analyses were performed by a contract research organization (Veramed Ltd, Twickenham, UK; funded by GSK) on behalf of, and with oversight from, employees of the sponsor.
Results

Study Population
A total of 16,485 patients were included in the intent-to-treat efficacy population. The patients were 65 years of age (SD 8 yr), had a post-bronchodilator FEV 1% predicted at screening of 60% (SD 6%), were predominately men (75%), and had a smoking history of 41 pack-years (SD 24 pack-years). Further information is available elsewhere (6) . Approximately onethird (6,464; 39%) of patients reported having at least one eCOPD in the year before study entry. Of these, 2,444 (15%) patients had two or more eCOPD in the year before study entry, and 2,205 (13%) experienced at least one eCOPD that required hospitalization in the previous year.
Overall Effect on eCOPD
The rates of moderate and/or severe eCOPD are presented in Table 1 . Treatment with FF/VI reduced the rate of eCOPD by 29% (95% confidence interval [CI], 22-35; P , 0.001) compared with placebo (Table 1) . Treatment with FF/VI reduced the rate of eCOPD by 19% (95% CI, 12-26; P , 0.001) compared with FF, which reflected the contribution of VI to the combination, and reduced the rate of eCOPD by 21% (95% CI, 14-28; P , 0.001) compared with VI, reflecting the contribution of FF to the combination. The risk of a first moderate and/or severe eCOPD was reduced with FF/VI compared with placebo by 21% (95% CI, 14-27; P , 0.001) ( Figure 1 ). All other comparisons for time to first analyses are presented in Table E1 in the online supplement. The effect of FF/VI in patients with at least 52 weeks of study drug exposure revealed a consistent effect throughout the follow-up period (data not shown).
Treatment with FF/VI reduced the rate of hospitalized patients with eCOPD by 27% (95% CI, 13-39; P , 0.001) compared with placebo (Table 1) . Treatment with FF/VI numerically reduced the rate of hospitalized patients with eCOPD by 11% (95% CI, 26 to 25; P = 0.204) compared with FF, which reflected the contribution of VI to the combination, and the rate of eCOPD by 9% (95% CI, 28 to 24; P = 0.282) compared with VI, which reflected the contribution of FF to the combination. The risk of a first hospitalized patient with eCOPD was reduced with FF/VI compared with placebo by 22% (95% CI, 8233; P = 0.002) ( Figure 1 ). All comparisons for time to first analyses are presented in Table E1 .
There appeared to be a higher probability of patients experiencing exacerbations in the winter than in the summer, although the treatment effect was similar for the winter exacerbations as for the summer exacerbations.
Effect on eCOPD as a Function of Subgroups
The rate ratios for the comparison of FF/VI with placebo for moderate and/or severe eCOPD for subgroups of interest are presented in Figure 2A . The reductions in rate of moderate and/or severe eCOPD were similar for all the subgroups (including the baseline percent of predicted FEV 1 cutoff at 60% and whether patients had a history of eCOPD or a history of hospitalized for eCOPD). The CIs for some subgroups were wide, reflecting the small number of subjects in that group. The event-based NNTs for subgroups by previous exacerbation history are shown in Table E2a . There was little difference in the NNT for preventing one on-treatment moderate and/or severe eCOPD (10 for FEV 1 , 60% and 10 for FEV 1 > 60% predicted) (data not shown). 
ORIGINAL ARTICLE
The rate ratios for the comparison of FF/VI with placebo for hospitalized patients with eCOPD for the subgroups of interest are presented in Figure 2B . The reductions in the rate of hospitalized patients with eCOPD were similar for most of the subgroups (including baseline percent predicted FEV 1 cutoff at 60% and whether patients had a history of eCOPD or a history of being hospitalized for eCOPD). The exception to this is for some of the race subgroups, in which there were very small numbers of patients and events. The eventbased NNTs for the comparison of FF/VI with placebo by exacerbation history are shown in Table E2a .
The rate ratios for the comparisons of FF/VI versus VI for moderate and/or severe eCOPD and for hospitalized patients with eCOPD for subgroups of interest are presented in the supplement ( Figures E1a, E1b , E2a, and E2b in the online supplement). The event-based NNTs for the comparison of FF/VI versus VI by exacerbation history are shown in Table E2b .
Effect on eCOPDs Treated with Antibiotics and Systemic Corticosteroids
Treatment with FF/VI reduced the rate of eCOPD treated with both AB and SCS by 38%. Substantial effects were also seen for those with eCOPD treated with SCS alone (61%), as well as those who required SCS with or without AB (45%) ( Table 2) . Treatment with FF/VI did not affect eCOPD treated with AB alone (Table 2) . For the patients with eCOPD who were treated with SCS with or without antibiotics, FF and VI individually also reduced the rate of eCOPD compared with placebo, although to a lesser extent than that of FF/VI. Neither FF nor VI reduced the rate of eCOPD treated with AB alone compared with placebo (12% increase and 6% increase, respectively) ( Table 2 ).
Discussion
SUMMIT is the largest survival study to date of an ICS and long-acting b-agonist in patients with COPD and heightened cardiovascular risk (6) . This study failed to show a significant effect of treatment with inhaled FF and VI on all-cause mortality or cardiovascular outcomes. In the present analysis, we demonstrated that FF/VI decreased the rate of moderate and/or severe eCOPD, eCOPD that required hospitalization, and eCOPD treated with SCS, which are all important respiratoryrelated outcomes. FF/VI also reduced exacerbations treated with both SCS and AB, whereas there was no effect on eCOPD treated with AB alone; for the latter, FF as monotherapy actually increased the risk by 12%. Although effect estimates varied, analyses of time to first exacerbation were not substantially different from those of rates. These data in a patient population that did not meet the traditional criteria for ICS therapy suggest that the combination of an ICS and LABA might be appropriate therapy for a broader range of individuals than those currently recommended by therapeutic strategy recommendations.
Our data strongly supported the idea that the combination of FF and VI could decrease the rate of moderate and/or severe eCOPD and prolonged the time to the first moderate and/or severe eCOPD compared with placebo. It was clear that both the FF and VI components contributed to these benefits. These results were similar to those documented in systematic reviews of previous randomized controlled trials (13) (14) (15) . In contrast to previous studies that generally included patients with more severe airflow obstruction, our findings were present in a population of patients with COPD with milder airflow obstruction, as suggested in a post hoc analysis of the large TORCH (Towards a Revolution in COPD Health) dataset (16) .
Similarly, our data supported that the combination of FF and VI decreased the rate of hospitalized patients with eCOPD and prolonged the time to the first eCOPD that required hospitalization compared with placebo. Both FF and VI contributed to the decrease in rates, although this effect was less consistent in the time-to-event analyses. Previous studies demonstrated inconsistent results on preventing hospitalizations (13) (14) (15) , but the large sample size and nature of our study allowed us to identify a positive effect of treatment. Treatment with FF/VI decreased the rate of moderate to severe eCOPD and prolonged the time to the first moderate and/or severe eCOPD to the same relative extent independent of the baseline FEV 1 percentage predicted. It should be noted that the percentage of individuals in SUMMIT who experienced a hospitalization in the year before study entry was higher than the percent of ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) Global Initiative for Chronic Obstructive Lung Disease 2 participants who experienced a hospitalization. In contrast, the hospitalization rate in SUMMIT was lower than that in ECLIPSE. The SUMMIT population, who by study design had cardiovascular risk, might be more likely to benefit from the combination of an ICS/LABA.
The positive effect of FF/VI on exacerbation numbers was entirely due to a reduction in the rate of eCOPD that required systemic steroids alone or eCOPD that required systemic antibiotics and steroids. There was little effect of the combination on eCOPD that required antibiotic therapy alone. Additional analyses suggested that this effect was more consistently driven by the ICS. Previous studies suggested that ICS-containing regimens decreased the likelihood of systemic steroid treated exacerbations (17) (18) (19) , although little was reported regarding the impact of ICS alone on these events (15) . Our data supported the results of previous controlled trials performed in patients with generally more severe airflow obstruction (13) (14) (15) . Our study suggested that ICS monocomponent therapy was associated with a greater risk of AB-treated events; this was also suggested by a separate group who compared ICS/LABA therapy with tiotropium (20) . Others documented that steroid-containing regimens could alter the lung microbial community in patients with COPD (21, 22) or alter the innate immune response (23) . We documented a lack of increased mortality associated with ICS monotherapy in subjects who were less severely obstructed (6) in contrast to the suggestion of increased mortality in subjects who experienced more severe obstruction (19) . Similarly, pneumonia was noted with ICS therapy, particularly in individuals with more severe disease (24) (25) (26) . This was not seen in the SUMMIT study, which enrolled subjects with COPD who had less severe obstruction (6) . Nevertheless, the possible adverse impact on AB-treated eCOPD with ICS monotherapy suggested that the recommendation to avoid ICS monotherapy in COPD (1) is likely wise.
Previous studies identified different phenotypes of acute exacerbation (27) that are related to differences in inflammatory patterns and possible exacerbation triggers (22) . Particular attention was given to the relationship between increased sputum or the systemic number of eosinophils and ICS response (28) . However, neither sputum nor systemic eosinophil determinations were included in SUMMIT, and we could not address this interesting question. In contrast, some authors suggested that subgroups might be identified by the presenting symptom complex (29, 30) and that therapeutic approaches might serve as a surrogate of the event trigger (31) and a phenotypic marker (32, 33) . Although we did not provide explicit guidance to practitioners on how to manage individual exacerbation events, our data suggested their choice of therapy for the individual event therapy was influenced by therapy with an ICS. There is a need for more studies to examine the characteristics of recurrent exacerbations within individual patients and a better characterization of why clinicians choose the treatment they do to manage these events. Although SUMMIT was not powered or designed to primarily address the issue of exacerbations in patients with moderate obstruction, the results provided potential insights into how ICS-based regimens could be considered in patients with COPD. The SUMMIT patient population's milder airflow limitation and lack of enrichment for eCOPD meant that the overall rates of moderate and/or severe eCOPD and eCOPD that required hospitalization were low but variable. There is debate about the usefulness of patient-based NNTs for recurrent events (in contrast to events that can only happen once, such as death). However, there is also challenge around the merits and interpretation of event-based NNTs for exacerbations (34) . Although NNTs are controversial and must be interpreted with caution, many clinicians find them helpful; we presented them because they might provide interesting insights into therapeutic recommendations. Regardless of the trial design (event driven or fixed duration), patients will have different treatment exposures for many different reasons, so the choice of study design does not affect the choice or interpretation of the NNT.
It would be inappropriate to recommend generalized treatment with inhaled ICS/LABA therapy for all patients with moderate airflow obstruction, particularly with recent data that suggests the exacerbation reduction benefit of a longacting antimuscarinic/LABA combination (35) . In contrast to current therapeutic guideline schema (1), baseline FEV 1 does not appear to influence therapeutic responsiveness to the combination of an ICS/LABA. A history of exacerbations does modify the likelihood of therapeutic response to this therapeutic combination versus placebo, although there was little difference in those with a history of one versus more than two moderate and/or severe events in the previous year. This was numerically different for a patient with history of being hospitalized for eCOPD. Additional analyses are needed to better define the optimal patient population with moderate airflow obstruction who may benefit from early therapy with a combination of an ICS/LABA. This would advance the evolving concepts of personalized therapeutic approaches (4).
Our results were limited by the negative primary endpoint of the overall SUMMIT study. As such, our results should be considered as nominal and should be interpreted with caution. We studied patients with overt or at heightened risk of cardiovascular disease, but we had no reason to believe that such patients would behave differently from other patients with COPD with a similar severity without this burdensome comorbidity. Our data on exacerbations contrasted with the negative findings of these therapies on overall and cardiac mortality, which suggested that we were able to manage the respiratory problems of the patients more effectively without influencing the mortality driven mainly by cardiac factors. This was in keeping with the idea that the cardiac and respiratory comorbidity of our patients coexisted without directly interacting, at least in patients with this degree of COPD. We did identify significant numbers of people who experienced exacerbations and were hospitalized as a result of this, even among patients with milder exacerbations than those who were included in earlier clinical trials. As the general management approach moves toward a more personalized approach (4), these data offer new insight into the potential role of combination inhaled therapy in appropriately identified individuals. n
